Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 557-565

  Scott, D J ^a   Parkes, A T ^a   Ponchel, F ^a   Cummings, M ^a   Poola, I ^b   Speirs, V ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Microarray; Tamoxifen resistance

Indexed keywords

4 HYDROXYTAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; PRIMER DNA; STEROID RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DNA MICROARRAY; DRUG SCREENING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, STEROID; RNA, MESSENGER; TAMOXIFEN;

EID: 38449110253     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.557     Document Type: Article

References (61)

1. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998.
2. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S and Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300, 2003. (Pubitemid 36126189)
3. Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112, 2002.
4. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
5. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MRJ and Hanby AM: Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol 5: 174-181, 2004 (erratum published in Lancet Oncol 5: 208, 2004).
6. Bardin A, Boulle N, Lazennec G, Vignon F and Pujol P: Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11: 537-551, 2004.
7. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS and Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167-1177, 1996.
8. McKenna NJ, Lanz RB and O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321-344, 1999. (Pubitemid 30649811)
9. Rosenfeld MG and Glass CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276: 36865-36868, 2001.
10. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P and Theillet C: In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4: 2925-2929, 1998.
11. Murphy LC, Simon SL, Parkes A, et al: Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 60: 6266-6271, 2000.
12. Bouras T, Southey MC and Venter DJ: Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 61: 903-907, 2001.
13. Smith CL, Nawaz Z and O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11: 657-666, 1997. (Pubitemid 27225293)
14. Xu J, Qiu Y, De Mayo FJ, Tsai SY, Tsai MJ and O'Malley BW: Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279: 1922-1925, 1998.
15. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361, 2003.
16. Lavinsky RM, Jepsen K, Heinzel T, et al: Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925, 1998.
17. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S and Sonoo H: Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin Cancer Res 6: 512-518, 2000. (Pubitemid 30111472)
18. Girault I, Lerebours F, Amarir S, et al: Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9: 1259-1266, 2003.
19. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P and Katzenellenbogen BS: An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 96: 6947-7001, 1999.
20. Furr BJ and Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205, 1984.
21. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after co-administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764, 2003.
22. Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85: 151-159, 2004.
23. Knowlden JM, Hutcheson IR, Jones HE, et al: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003.
24. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ and Speirs V: Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 197: 155-162, 2002.
25. Limer JL, Parkes AT and Speirs V: Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J Cancer 119: 515-521, 2006.
26. Ponchel F, Toomes C, Bransfield K, et al: Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 3: 18-31, 2003.
27. Brunner N, Frandsen TL, Holst-Hansen C, et al: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993.
28. Badia E, Duchesne M-J, Semlali A, et al: Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 60: 4130-4138, 2000.
29. Herman ME and Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to transhydroxytamoxifen. J Steroid Biochem Mol Biol 59: 121-134, 1996.
30. Rabenoelina F, Semlali A, Duchesne MJ, Freiss G, Pons M and Badia E: Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade. Int J Cancer 98: 698-706, 2002. (Pubitemid 34225619)
31. Hutcheson IR, Knowlden JM, Madden TA, et al: Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81: 81-93, 2003.
32. Sarvilinna N, Eronen H, Miettinen S, Vienonen A and Ylikomi T: Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. Int J Cancer 118: 832-840, 2006.
33. De Cremoux P, Tran-Perennou C, Brockdorff BL, et al: Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer 10: 409-418, 2003.
34. Fasco MJ, Amin A, Pentecost BT, Yang Y and Gierthy JF: Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen. Mol Cell Endocrinol 206: 33-47, 2003.
35. Shaw LE, Sadler AJ, Pugazhendhi D and Darbre PD: Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 99: 19-32, 2006.
36. Lykkesfeldt A, Madsen M and Briand P: Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54: 1587-1595, 1994. (Pubitemid 24106427)
37. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M and Lidereau R: Quantification of estrogen receptor α and β expression in sporadic breast cancer. Oncogene 20: 8109-8115, 2001.
38. Osipo C, Gajdos C, Li H, Chen B and Jordan VC: Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95: 1597-1608, 2003.
39. Jarvinen TAH, Pelto-Huikko M, Holli K and Isola J: Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade and proliferation rate in breast cancer. Am J Pathol 156: 29-35, 2000.
40. Omoto Y, Inoue S, Ogawa S, et al: Clinical value of the wildtype estrogen receptor beta expression in breast cancer. Cancer Lett 163: 207-212, 2001.
41. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P and Rochefort H: Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61: 2537-2541, 2001.
42. Naundorf H, Becker M, Lykkesfeldt AE, et al: Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Br J Cancer 82: 1844-1850, 2000.
43. Anzick SL, Kononen J, Walker RL, et al: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968, 1997.
44. Thenot S, Charpin M, Bonnet S and Cavailles V: Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 156: 85-93, 1999.
45. Vienonen A, Miettinen S, Manninen T, Altucci L, Wilhelm E and Ylikomi T: Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. Eur J Endocrinol 148: 469-479, 2003. (Pubitemid 36527419)
46. Shang Y and Brown M: Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468, 2002.
47. Fleming FJ, Hill ADK, McDermott EW, O'Higgins NJ and Young LS: Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by β-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 89: 375-383, 2004.
48. Lanz RB, McKenna NJ, Onate SA, et al: A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97: 17-27, 1999.
49. Chooniedass-Kothari S, Hamedani MK, Troup S, Hube F and Leygue E: The steroid receptor RNA activator protein is expressed in breast tumor tissues. Int J Cancer 118: 1054-1059, 2006.
50. Delage-Mourroux R, Martini PGV, Choi I, Kraichely DM, Hoeksema J and Katzenellenbogen BS: Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J Biol Chem 275: 35848-35856, 2000.
51. Martini PGV and Katzenellenbogen BS: Modulation of estrogen receptor activity by selective coregulators. J Steroid Biochem Mol Biol 85: 117-122, 2003. (Pubitemid 37011090)
52. Mussi P, Liao L, Park SE, et al: Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland. Proc Natl Acad Sci USA 103: 16716-16721, 2006.
53. Kurokawa H, Lenferink AEG, Simpson JF, et al: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894, 2000.
54. Liu XF and Bagchi MK: Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem 279: 15050-15058, 2004.
55. Morrison AJ, Herrera RE, Heinsohn EC, Schiff R and Osborne CK: Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol 17: 1543-1554, 2003.
56. Chan CM, Lykkesfeldt AE, Parker MG and Dowsett M: Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. Clin Cancer Res 5: 3460-3467, 1999.
57. Keeton EK and Brown M: Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19: 1543-1554, 2005.
58. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574, 2003.
59. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR and Katzenellenbogen BS: Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64: 1522-1533, 2004. (Pubitemid 38235626)
60. Reubi JC, Gugger M, Waser B and Schaer JC: Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61: 4636-4641, 2001.
61. Kuang WW, Thompson DA, Hoch RV and Weigel RJ: Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic Acids Res 26: 1116-1123, 1998.